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Tumor cells secrete polypeptide growth factors that may induce autocrine, paracrine, and endocrine effects (7). The autocrine stimulus supports tumor cell proliferation, whereas the paracrine loop allows a growing tumor mass to recruit new blood vessels for its nourishment. This tumor angiogenesis is not only essential for the growth of the local tumor-it also provides the route for distant metastasis of tumor cells (2). Data from different solid tumors (e.g., breast, prostate, or lung) have supported this principle, and the rate of metastasis in patients has been associated directly with the number of capillaries detectable in a given primary tumor (3, 4) .
This direct role of polypeptide growth factors in local tumor angiogenesis, as well as an indirect role in tumor metastasis, makes these growth factors promising targets for a drug treatment that selectively disrupts the tumor homeostasis (5,6). This approach becomes even more tempting when one considers that in the adult, angiogenesis is absent with a very few, well-defined exceptions (e.g., menstrual cycle, placenta growth, or wound healing) (5,7). A number of polypeptide growth factors, in particular endothelial cell growth factors, have marked affinity for the glycosaminoglycan heparin and are commonly known as heparin-binding growth factors (HBGFs) (8). This common feature of *See "Notes" section following "References." different growth factors (9) has prompted the use of polysulfated compounds to try to block HBGFs (10) . One of the early compounds used was the polysulfated aromatic compound suramin (77). However, because of systemic toxic effects and an extremely long half-life of more than 2 months, this drug is difficult to use (77), and we sought to find a less toxic compound with a similar mechanism of action. Earlier, we reported that the polysulfated sugar pentosan polysulfate (PPS) is very effective in vitro against HBGFs released from tumors and in vivo to inhibit growth in animal tumor models (72-74).
The preclinical data described above prompted a phase I study in cancer patients, and here, we report on a bioassay that we have developed to detect PPS-induced anti-HBGF activity in human serum samples. Furthermore, we show the biological activity of this drug, using sera from some patients in this study. PPS is used as an anticoagulant in Europe because of its heparin-like activity, and the major toxic effect expected for this drug results from its inhibition of coagulation (15). We have, therefore, also studied the effect of PPS on a coagulation parameter (activated partial thromboplastin time [aPl'l'J) in vitro and show that high concentrations of biologically active circulating anti-HBGF activity can be achieved at doses of PPS that do not substantially affect coagulation. These studies establish a potential therapeutic window for PPS treatment of patients and provide an in vitro assay of drug activity that should prove useful for monitoring in future studies.
Patients and Methods

Healthy Subjects
Fresh blood samples (10 tnL) were donated by six different members of our staff. PPS was added at different concentrations (0-10 (ig/mL) into the collection tubes immediately after blood was drawn. One aliquot from each sample was used to assay aPTT in our hospital laboratory (Coag-a-Mate X-2, General Diagnostics, Newark, N.J.). Serum was prepared from the rest of the blood samples by centrifugation. After heat treatment to inactivate the serum (55 °C for 1.5 hours), the samples were used in the cell proliferation assays described below.
Patients
From four of the patients participating in a phase 1 clinical trial with PPS, blood samples were drawn before and up to 4 hours after the first subcutaneous injection of PPS (15 mg/m 2 ). These blood samples were assayed for aPTT, and sera were separated, heat treated (see above), and frozen at -20 °C until further use. The investigations involving patients were performed after obtaining informed consent from each patient and after approval by our institutional review board in accordance with guidelines established by the National Institutes of Health.
Cell Proliferation Assays
The SW-13 (human adrenal carcinoma) cell line was obtained from American Type Culture Collection (Rockville, Md.). SW-13 cells were propagated in Improved Minimal Essential Media (IMEM) (Biofluids, Rockville, Md.) with 10% fetal calf serum (FCS; GIBCO BRL, Gaithersburg, Md.). For in vitro studies, SW-13 cells were plated into 24-well plates at 5000-20000 cells per well in 1 mL of medium or in 96-well plates at 500-1000 cells per well in 100 u,L of medium (13.14). Different additions to the growth media (i.e., human serum and drugs) are indicated in the respective figures and in the text. Two to six wells were run for each data point. The cultures were allowed to grow in 5% carbon dioxide for 4-5 days at 37 °C. The cells in the 24-well plates were then detached with trypsin-EDTA (GIBCO BRL), and their number was estimated using a Coulter counter. Cells growing in 96-well plates were stained with Mosmann's tetrazolium dye (16) according to the specifications of the manufacturer (MTT [3-{4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazoliurn bromide] assay, PROMEGA, Madison, Wis.). The number of vital cells in the plates was estimated using an enzyme-linked immunosorbent assay reader at 570 nm with a reference wavelength of 630 nm.
Data Evaluation
To evaluate data, we calculated analysis of variance via the Newman-Keuls Test using the computer program PHARM/PCS version 4.2 (Pharmacologic Calculations Program, PC5, New York, N.Y.). Unless stated otherwise, mean values plus or minus standard deviation of the mean are shown in the graphs.
Drugs
PPS (FIBREZYM) was a gift from BeneChemie (Munich, Germany). The HBGF Kaposi's fibroblast growth factor (K-FGF) was prepared as described earlier (17).
Results
Selectivity of PPS in Vitro
In a first series of in vitro experiments, we compared the effect of different concentrations of PPS (concentration response) on coagulation with that on HBGF-dependent cell proliferation (Figs. 1 and 2) . For the coagulation studies, each blood sample drawn from six volunteers was divided among seven tubes that contained different concentrations (0-10 u.g/mL) of PPS. The coagulation parameter aPTT was measured in these samples, and the respective data are shown in Fig. 1 . A concentration-dependent increase of the aPTT is apparent. Above 1.25 u,g/mL of PPS, this increase is statistically significant relative to control values (7><.O5). The aPTT values achieved during standard heparin therapy are shown for comparison and are reached at PPS concentrations of approximately 2.5 u.g/mL (Fig. 1, shaded area) .
In parallel with these in vitro coagulation studies, we established the concentration response of PPS on HBGF-dependent cell proliferation. These assays were carried out using proliferating SW-13 cells in standard growth media (IMEM plus 10% FCS) and had no human serum added (75). SW-13 cells were chosen as indicator cells because their proliferation on dish surfaces depends on the presence of endogenously produced HBGFs (in particular, basic fibroblast growth factor) and is highly sensitive to inhibition by polysulfates such as PPS or suramin (13, 17, 18) . In the experiment shown in Fig. 2 , even the lowest concentration of PPS (0.1 u-g/mL) inhibited cell proliferation by more than 50%. This inhibition was reversed by addition of excess K-FGF (100 ng/mL) (8), confirming the specificity of the inhibitory action of PPS on cell proliferation. After comparing data from these in vitro studies, we concluded that the PPS concentration at which an effect on HBGF-dependent cell proliferation was observed is less than one tenth the concentration that affected coagulation.
Preparation of Human Serum Samples for Use in Cell Proliferation Assays
In the next series of experiments, we established experimental conditions that allowed use of human serum samples in the cell proliferation assay. PPS (25 |xg/mL) was added to a subset of blood samples from different volunteers and serum was separated, pretreated as Obviously, adult human serum that was above, and used in the SW-13 cell pro-heat inactivated for 1.5 hours lacks liferation assays. Fig. 3 shows cell cytotoxic effects that are associated counts from one of these experiments, with complement activity present in nonheated serum. The effect of PPS added to the samples is retained. This result is supported by concentration response curves of PPS using blood samples from six different healthy volunteers as a source of serum (Fig.  4) . The IC 50 (i.e., the concentration that causes 50% inhibition of growth) value of about 0.1 fig/mL agrees closely with results from earlier in vitro studies (13, 14) . Heat inactivation of serum for up to 6 hours did not affect the result (data not shown), and we used a 1.5-hour heat inactivation of serum as our standard protocol.
Results From Patients Treated With PPS
The above protocol was applied to blood samples obtained from patients receiving the first dose of PPS (15 mg/m 2 , injected subcutaneously). Blood samples were drawn before and up to 4 hours after injection of PPS, and cell proliferation in the presence of the respective samples was measured. In addition, aPTT values were recorded. Raw data from one patient are shown in Fig. 5 . The SW-13 cell number increased by fourfold in the presence of the serum sample obtained before onset of the PPS treatment (time = 0 hours; Fig. 5 ). Addition of an excess of PPS (25 u.g/mL) to this sample resulted in a number of cells at or slightly below the number of cells originally plated. In contrast to the pretreatment values, cell proliferation in the presence of serum samples obtained after PPS treatment was inhibited by 65%-75% (time = 1, 2, 3, and 4 hours; Fig. 5 ). Preliminary studies indicate that growth factorinhibitory activity can be detected for 6-8 hours after a single dose of PPS and is below detection after 12 hours (data not shown).
Data from four different patients and from separate experiments were pooled after subtracting the number of SW-13 cells plated in the respective experiments. As illustrated in Fig. 6 , the cell number drops to about 25%-35% of that observed in the control experiment in the presence of serum samples obtained after PPS treatment (open circles). At the same time, the aPTT values were not substantially affected (asterisks; Fig. 6 ). When excess PPS was added to the SW-13 cell assay, the number of cells after the 4-5 days of incubation was still close to or below the number of cells originally plated (closed circles; Fig. 6 ). Addition of excess K-FGF restored cell proliferation to or above control values (closed squares; Fig. 6 ). From these results with samples from PPS-treated patients, we concluded that significant amounts of biologically active PPS (or active metabolites of PPS) circulate in serum after treatment with a dose of PPS that did not affect coagulation. The minimal additional effect of exogenous PPS added to the samples from PPS-treated patients and the reversal of this inhibition by K-FGF support the specificity of the assay for HBGFs (74).
_15000 -E
.
Discussion
Assessment of PPS dosage and timing in previous clinical studies has relied on coagulation parameters because of the drug's heparin-like activity (75, 79) . From these studies and from studies with radioactive tracers (79), it appears that PPS behaves in a manner pharmacokinetically similar to that of heparin. Like heparin, it shows poor oral absorption, and the drug is eliminated with a half-life of 2-4 hours (heparin's half-life is 0.5 hours). In our studies, we wished to avoid the anticoagulant dose range of PPS since we were'interested in its antigrowth factor activity. This interest was based on preclinical studies from our laboratories showing efficacy of PPS in animal tumor models (75, 74) , and it prompted a phase I trial of PPS in cancer patients. Our previous animal studies had shown that the antitumor activity in animals occurs at doses lower than those required to affect coagulation; therefore, we attempted to develop a bioassay based on the anti-HBGF activity of PPS.
The reasons for using a bioassay versus a chemical detection method (e.g., high-pressure liquid chromatography) of PPS were twofold: 1) PPS is a semisynthetic compound that consists of a heterogeneous mixture of polysulfates of different molecular mass. The raw material for PPS is extracted from beechwood shavings and is chemically (20, 22) . In our present study, we used the coagulation parameter aPTT to define the threshold of the anticoagulation activity of PPS. Parallel cell proliferation studies with the same samples or material established the selectivity of PPS as an anti-HBGF drug. Under the conditions of our initial in vitro studies ( Figs. 1 and 2 ), PPS inhibited SW-13 cell proliferation at less than one tenth the concentration at which it affected aPTT. The later studies, with PPS added to blood samples from volunteers or with serum samples from patients that had been previously treated with PPS, yielded similar results.
The major technical "trick" that allowed us to use serum from volunteers or from patients in our cell proliferation studies was to heat inactivate cytotoxic material (mainly complement) present in this adult serum (Fig.  3) . Other methods, such as gel filtration or dialysis, failed to generate usable serum preparations (data not shown). Generally speaking, cytotoxic drugs present in heat-inactivated sera might also be detected in similar cell proliferation assays if appropriately sensitive target cells are used.
The most impressive data were obtained with serum samples from patients after PPS treatment (Fig. 6) . Even at the dilution of 1:10 used in these assays, more than 50% of SW-13 cell proliferation was inhibited by drug present in these samples. This result fits well with the in vitro data and with the aPTT measurements observed in parallel, and we wish to highlight this point: No substantial elevation of aPTT was detected in these patients (Fig. 6) . Based on our in vitro coagulation studies (Fig. 1) , the PPS concentration should thus not exceed 2 u.g/mL. The respective serum samples were diluted by 1:10 in the proliferation assay and hence the final concentration would be 0.2 u.g/mL at maximum. As Figs. 2 and 3 illustrate, a greater than 50% inhibition of cell proliferation is to be expected at this concentration of PPS, and our experimental data in Fig. 6 validate this prediction.
One potential shortcoming in the above line of reasoning could be the appearance of active metabolites of PPS during chronic treatment. In particular, active metabolites with a longer elimination half-life than the parent compound could tilt the balance in favor of anti-HBGF or anticoagulant activities and could increase or reduce the selectivity of the drug with respect to these two effects. Preliminary studies with chronic administration of PPS and monitoring of parameters for both effects indicate that active metabolites do not seem to play a significant role. (Zugmaier G, Wellstein A: unpublished data).
PPS has significant growth-inhibitory effects on HBGF-dependent cell proliferation at concentrations that do not affect aPTT. This finding is apparent in in vitro assays with PPS added to blood samples from healthy volunteers as well as in blood samples obtained from patients treated with PPS. The assay presented here could be useful to determine doses and scheduling of treatment in studies evaluating PPS as an antitumor agent.
